No Data
The Chief Scientific Officer of Asymchem Laboratories (06821.HK) is retiring and will be appointed as a consultant.
Asymchem Laboratories (06821.HK) announced that James Randolph Gage has applied to resign as Chief Scientific Officer (CSO) due to reaching retirement age. After leaving, James Randolph Gage will not hold any position in the company, but the company will hire him as a consultant to continue providing technical guidance and support. Currently, James Randolph Gage does not Hold any shares in the company, and his departure will not affect the normal operation of the company's production activities.
Express News | Asymchem Laboratories: Senior executive James Randolph Gage retires from his position.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Express News | Ping An Securities Pharmaceutical Industry 2025 Annual Strategy Report: Exploring new growth from payment sources, focusing on innovation, going overseas, equipment upgrades, and Consumer recovery.
Express News | CITIC Construction Investment: Optimistic about investment opportunities in the pharmaceutical industry in 2025, focusing on new volume and industry integration opportunities
